Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of “Buy” from Analysts

Cabaletta Bio, Inc. (NASDAQ:CABA) has been given an average recommendation of “Buy” by the ten analysts that are presently covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $28.10.

A number of analysts have weighed in on CABA shares. UBS Group started coverage on shares of Cabaletta Bio in a research report on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 price target on shares of Cabaletta Bio in a report on Friday, June 21st. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a report on Tuesday, September 17th. Evercore ISI cut their price target on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. Finally, Wells Fargo & Company cut their price target on shares of Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, August 12th.

Hedge Funds Weigh In On Cabaletta Bio

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in Cabaletta Bio by 65.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company’s stock worth $140,000 after buying an additional 3,244 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Cabaletta Bio in the first quarter valued at $147,000. Birchview Capital LP bought a new stake in Cabaletta Bio in the fourth quarter valued at $227,000. Bayesian Capital Management LP bought a new stake in Cabaletta Bio in the first quarter valued at $191,000. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Cabaletta Bio in the first quarter valued at $305,000.

Cabaletta Bio Price Performance

Shares of Cabaletta Bio stock opened at $4.66 on Thursday. Cabaletta Bio has a fifty-two week low of $3.47 and a fifty-two week high of $26.35. The firm has a market capitalization of $224.97 million, a P/E ratio of -2.73 and a beta of 2.39. The company’s 50 day moving average price is $4.64 and its two-hundred day moving average price is $8.58.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). On average, analysts expect that Cabaletta Bio will post -2.28 earnings per share for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.